Prostate Cancer Diagnosis and Treatment Options by Stage

Prostate cancer is usually found in stages, starting with simple exams and tests. Doctors first review your health history – asking about urinary symptoms (trouble starting or stopping urine, urgency, etc.), family history of prostate cancer, and overall health They also do a physical exam. In particular, a digital rectal exam (DRE) may be done: the doctor inserts a gloved finger into the rectum to feel the prostate for size, shape and any unusual lumps. (Some experts now rely more on imaging instead of routine DRE, but it is still often mentioned in initial evaluations.)

PSA Blood Test: A blood test measures prostate-specific antigen (PSA), a protein made by the prostate. Higher-than-normal PSA levels can suggest prostate cancer, but can also occur with benign prostate enlargement or inflammation. Because PSA can be affected by many factors, doctors usually look at PSA trends over time and may use risk calculators to decide if more testing is needed. (For example, a steadily rising PSA might prompt a biopsy even if the level is only modestly elevated.)
Imaging and Biopsy: If there is concern (due to exam or PSA), imaging scans like ultrasound or MRI are used to look more closely at the prostate and guide biopsies. A multiparametric MRI (an advanced prostate MRI) can help pinpoint suspicious areas in the gland. During the biopsy procedure, doctors use imaging (usually a transrectal ultrasound or MRI) to guide a thin needle into the prostate. The needle collects 10–12 small core samples of tissue from different parts of the prostate, especially any abnormal areas. These samples are sent to a lab, where a pathologist looks for cancer cells. If cancer is found, it is given a Gleason score (Grade Group), which tells how aggressive the cancer looks under the microscope.
Staging Tests: Once cancer is confirmed, additional tests are done for higher-risk cases to see if it has spread. Imaging such as a bone scan (to check for spread to bones) or a CT scan (to check lymph nodes and organs) may be ordered. Newer scans – for example, a PSMA PET scan – use a radioactive tracer that targets prostate cancer cells to find even small metastases outside the prostate. The results of these tests (along with PSA and Gleason score) determine the cancer’s stage and risk level.

Treatment Options by Risk Category

After diagnosis, prostate cancers are grouped by risk (based on PSA, Gleason score, and tumor stage). This helps doctors recommend standard treatment options:

Low-risk (localized) prostate cancer: These are small, slow-growing tumors confined to the prostate. Most men in this group are offered active surveillance (regular monitoring with PSA tests, exams and periodic biopsies) because many low-risk cancers grow so slowly they may never cause harm. If the patient prefers treatment, or if the cancer shows signs of growing, curative options like surgery or radiation are available. Radiation can be external beam or brachytherapy (“seed” implants); sometimes surgery (radical prostatectomy) is chosen upfront.
Intermediate-risk prostate cancer: These cancers have a higher chance of growing or spreading than low-risk ones. Standard options include radical prostatectomy (surgery) or radiation therapy. Radiation is often given with a few months of hormone therapy to improve effectiveness. External beam radiation may be combined with short-term hormones, and in some cases a combination of external radiation plus brachytherapy (with or without hormones) is used. The choice among these depends on the patient’s preferences and overall health.
High-risk or locally advanced prostate cancer: These tumors have high PSA or Gleason scores or have grown beyond the prostate. Treatment usually involves combination therapy. A common approach is external beam radiation plus long-term hormone therapy (often 1–3 years of androgen-blocking drugs). For very aggressive cancers, newer drugs like abiraterone may be added to the hormone therapy. Some men may have surgery (radical prostatectomy); if pathology after surgery shows high-risk features (like positive margins or node involvement), doctors often add radiation therapy (and sometimes hormones) afterward. The goal is to use multiple modalities to control the cancer.
Metastatic prostate cancer: When cancer has spread to distant sites (e.g. bones or lymph nodes), the focus is on systemic treatment. Hormone therapy (androgen deprivation) is the backbone, often combined with newer targeted hormonal drugs (such as abiraterone, apalutamide or enzalutamide). For many men with extensive disease, chemotherapy (like docetaxel) is added to hormone therapy. Other treatments may include radiopharmaceuticals (radioactive drugs for bone metastases) and therapies to relieve symptoms (for example, radiation to painful bone lesions). Because metastatic prostate cancer is generally incurable, the main goals are to control the cancer, relieve symptoms, and maintain quality of life.

Each patient’s case is unique, so doctors use this diagnostic information and risk assessment to tailor the best treatment plan. Regular follow-up (for example, PSA checks) is critical to monitor response or detect any recurrence.